OESCLIM: an advanced delivery system for HRT.
OBJECTIVE
Transdermal estradiol offers a number of advantages over traditional oral routes of hormone replacement therapy (HRT) because it is not subject to the hepatic first-pass effect. However, transdermal systems need to balance adhesion, tolerability, and flux if they are to be effective. OESCLIM is a transdermal 17-beta estradiol HRT system designed to address the problems of conventional transdermal patches and offer optimal adhesion and tolerability in an effective HRT system. This paper reviews some of the data on OESCLIM with reference to its delivery system.


RESULTS
The innovative technology used in OESCLIM results in a smooth pharmacokinetic profile throughout the 3-4 day application period. In recent pharmacokinetic studies, OESCLIM 50 provided a more consistent release of hormone than Estraderm TTS 50 and higher mean estradiol levels than Systen and Vivelle. This smooth pharmacokinetic profile is also maintained whether OESCLIM is attached to different body sites. The local skin tolerability of OESCLIM is good. One study reported that OESCLIM 50 caused less than half the number of skin reactions as Estraderm TTS 50 (4.2% compared to 9.5%). OESCLIM has also been shown to have fewer detachments than Estraderm TTS (6% compared to 11%). Both differences were statistically significant (P < 0.001). A study has shown OESCLIM to be as effective as Estraderm TTS at reducing vasomotor symptoms even in highly symptomatic women.


CONCLUSIONS
OESCLIM is a very good first-line choice for estrogen replacement therapy (ERT) or HRT providing effective therapy with optimum adhesion, flux and tolerability profiles.
Munoz
A
A
Laboratoires Fournier, Daix, France.
D000279:Administration, Cutaneous; D016503:Drug Delivery Systems; D004958:Estradiol / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics; D015914:Estrogen Replacement Therapy / Q000009:adverse effects / Q000379:methods*; D005260:Female; D006801:Humans
D004958:Estradiol